Tuberculosis
Should be taken with food.
Oral Tuberculosis Adult: As part of a multidrug regimen: For standard unsupervised 2-mth treatment: <50 kg: 1.5 g daily; >50 kg: 2 g daily. For intermittent supervised 2-mth treatment: <50 kg: 2 g 3 times wkly; >50 kg: 2.5 g 3 times wkly. Hepatic impairment: Severe: Contraindicated.
Oral Tuberculosis Child: As part of a multidrug regimen: For standard unsupervised 2-mth treatment: 35 mg/kg daily. For intermittent supervised 2-mth treatment: 50 mg/kg 3 times wkly.
Renal impairment: May need dose reduction.
Hypersensitivity; existing liver disease; acute gout or hyperuricaemia. Porphyria. Pregnancy and lactation.
Pyrazinamide may be bacteriostatic or bactericidal in action, depending on the concentration of the drug attained at the site of the infection and the susceptibility of the infecting organism. Its activity appears to partly depend on conversion of the drug to pyrazinoic acid (POA), which lowers the pH of the environment below that which is necessary for growth of Mycobacterium tuberculosis. Susceptible strains of M. tuberculosis produce pyrazinamidase, an enzyme that deaminates pyrazinamide to POA, and the in vitro susceptibility of a given strain of the organism appears to correspond to its pyrazinamidase activity.
Patient w/ DM, history of gout. Mild to moderate hepatic and renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor liver function, serum uric acid, sputum culture; chest x-ray 2-3 mth into treatment and at completion.
1-10% Malaise,Nausea,Vomiting,Anorexia,Arthralgia,Myalgia <1% Fever,Rash,Itching,Acne,Photosensitivity,Gout,Dysuria,Porphyria,Thrombocytopenia,Hepatotoxicity,Interstitial nephritis Potentially Fatal: Severe liver damage, fulminant hepatitis.
Antagonises the effect of uricosuric agents (e.g. probenecid, sulfinpyrazone). May reduce the contraceptive effect of oestrogens. May inactivate oral typhoid vaccine. May increase the serum concentration of ciclosporin. May enhance the hepatotoxic effect of rifampicin.